Priorities for antiretroviral drug optimization in adults and children report of a CADO, PADO and HIVResNet joint meeting

Übersicht

The CADO-4 and the PADO-5 meetings were held virtually between September and October 2021 to promote alignment and synergy across these two expert groups and to develop a shared vision for the future of HIV treatment optimization.

Recognizing the critical role of HIV drug resistance in the ART drug optimization framework and the impact of drug resistance on ARV drug regimen durability and sequencing in the context of current and future options for second- and third-line therapy, the HIV Drug Resistance Network (HIVResNet) was also convened during the same period. This strategic alignment enabled HIVResNet to provide relevant input to the CADO-4 and PADO-5 priority-setting processes and to address drug resistance implications in the selection of new ART strategies, the alignment of drug regimens for HIV treatment and prevention and the impact of new ARV drugs on viral load suppression among pregnant women and the future role of postnatal prophylaxis.

This joint report summarizes the key discussions and conclusions of CADO-4, PADO-5 and WHO HIVResNet meetings.